SR9011
Also known as: Rev-ErbA agonist SR9011, stenabolic analogue
Rev-ErbA alpha/beta agonist studied for circadian modulation, lipid metabolism, and wakefulness research.
Quick Reference
SR9011 - Research Images
PSO vial render · Scientific images from Wikipedia · Tap to enlarge
Overview
Chemical compound
SR9011 is a research drug that was developed by Professor Thomas Burris of Scripps as an agonist of Rev-ErbAα with a half-maximum inhibitory concentration (IC50) = 790 nM for Rev-Erbα and IC50 = 560 nM for Rev-ErbAβ. It has been used in the study of the regulation of the circadian rhythm and its links to immune system function, inflammation and cancer.
Mechanism of Action
SR9011 is a research drug that was developed by Professor Thomas Burris of Scripps as an agonist of Rev-ErbAα
What Researchers Are Saying
Community Reports - Not Medical Advice
The following is aggregated from public forums, Reddit, and research communities. These are anecdotal reports from researchers only - not verified clinical data and not a recommendation of any kind.
SR9011 (also known as Rev-ErbA agonist SR9011, stenabolic analogue) is studied within the selective androgen receptor research community. Rev-ErbA alpha/beta agonist studied for circadian modulation, lipid metabolism, and wakefulness research.
Last updated October 28, 2026
Research status: limited. SR9011 appears across selective androgen receptor research forums and academic literature. Researchers note this compound falls in the sarms category.
Last updated October 28, 2026
What Do You Think of This Peptide?
Share your opinion or research experience with SR9011. Comments are reviewed before appearing.